Specialties – Page 87

Pirtobrutinib Demonstrates Superior Efficacy and Tolerability in cBTKi-Pretreated CLL/SLL: Insights from the BRUIN CLL-321 Phase III Trial

By MedXY 08/01/2025

Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.

Cardiology Clinical Updates Medical News Neurology Specialties

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

By MedXY 08/01/2025

A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.

$Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients$

Clinical Updates Hematology-Oncology Medical News Specialties

Long-Term Outcomes of Cilta-Cel CAR-T Therapy in Relapsed/Refractory Multiple Myeloma: Five-Year Remission Achieved in One-Third of Patients

By MedXY 08/01/2025

A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.

Clinical Updates Gastroenterology Medical News Specialties

Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results and Clinical Implications

By MedXY 08/01/2025

A phase 2b trial found that efruxifermin did not significantly improve fibrosis at 36 weeks in patients with compensated cirrhosis due to MASH, though longer-term benefit was suggested at 96 weeks.

Clinical Updates news Oncology Specialties

First-Line Encorafenib, Cetuximab, and mFOLFOX6 in BRAF V600E–Mutated Metastatic Colorectal Cancer: Clinical Impact from the BREAKWATER Trial

By MedXY 08/01/2025

Combination therapy with encorafenib, cetuximab, and mFOLFOX6 significantly improves progression-free and overall survival compared to standard care in first-line treatment of BRAF V600E–mutated metastatic colorectal cancer.

Cardiology Clinical Updates news Specialties

Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications

By MedXY 08/01/2025

Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.

news Respiratory Specialties

As-Needed Albuterol–Budesonide Therapy in Mild Asthma: Clinical Impact and Comparative Evidence

By MedXY 08/01/2025

As-needed albuterol–budesonide significantly reduces severe exacerbations in mild asthma compared to albuterol alone, with comparable safety. Two pivotal trials confirm efficacy across lung function and exacerbation outcomes.

Neurology Specialties

Tenecteplase in Modern Stroke Care: Comparative Insights from Recent Chinese Clinical Trials

By MedXY 08/01/2025

Three major Chinese trials examine intravenous and intra-arterial tenecteplase as adjuncts to thrombectomy in acute large-vessel occlusion stroke, revealing functional benefit with intravenous use before thrombectomy but not after reperfusion.

Clinical Updates news Oncology Specialties

Inavolisib Improves Overall Survival in PIK3CA-Mutated Advanced Breast Cancer: Results from the INAVO120 Study

By MedXY 08/01/2025

Inavolisib combined with palbociclib and fulvestrant significantly prolongs overall survival in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, but increases certain toxicities.

news Oncology Respiratory Specialties

Comparative Efficacy and Safety of Prednisone and Methotrexate as First-Line Treatments for Pulmonary Sarcoidosis

By MedXY 08/01/2025

A recent multicenter trial demonstrates methotrexate's noninferiority to prednisone in improving lung function at 24 weeks in pulmonary sarcoidosis, with distinct side-effect profiles informing treatment choices.

Clinical Updates Hematology-Oncology news Specialties

Advances in Graft-versus-Host Disease Prophylaxis: Cyclophosphamide and Cyclosporin in Allogeneic Stem Cell Transplantation

By MedXY 08/01/2025

Post-transplant cyclophosphamide plus cyclosporin significantly improves GVHD-free, relapse-free survival compared to standard prophylaxis in matched related donor stem cell transplantation.

Clinical Updates Gastroenterology news Specialties

Multidose Ondansetron After Emergency Visits: Reducing Gastroenteritis Severity in Children

By MedXY 08/01/2025

A randomized trial shows that multidose ondansetron after pediatric ED visits for gastroenteritis reduces moderate-to-severe illness, though impact on vomiting duration and healthcare utilization is limited.

Clinical Updates Gastroenterology news Specialties

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Clinical Updates news Oncology Specialties

Perioperative Durvalumab Plus FLOT Improves Event-Free Survival in Resectable Gastric and Gastroesophageal Junction Cancer: Results from the MATTERHORN Trial

By MedXY 07/31/2025

Adding perioperative durvalumab to standard FLOT chemotherapy significantly improves event-free survival and pathological response in resectable gastric and gastroesophageal junction adenocarcinoma without increasing severe adverse events.

news Oncology Specialties

Trastuzumab Deruxtecan versus Ramucirumab plus Paclitaxel in HER2-Positive Metastatic Gastric Cancer: Advances from Phase 3 Trials and Real-World Data

By MedXY 07/31/2025

Phase 3 data show trastuzumab deruxtecan significantly improves survival over ramucirumab plus paclitaxel in HER2-positive metastatic gastric cancer, with manageable safety, supported by real-world evidence from Japan.

Clinical Updates news Oncology Specialties

Tarlatamab versus Chemotherapy in Relapsed Small-Cell Lung Cancer: Results from the Phase 3 DeLLphi-304 Trial

By MedXY 07/31/2025

Tarlatamab significantly improves overall survival and reduces severe adverse events compared to chemotherapy in patients with small-cell lung cancer progressing after platinum-based therapy.

Infectious Diseases Specialties

Mass Ivermectin Administration for Malaria Control: Translational Insights from Recent Cluster-Randomized Trials

By MedXY 07/31/2025

Recent cluster-randomized trials in Kenya and Burkina Faso provide mixed but informative evidence on the efficacy and safety of mass ivermectin administration for malaria control, highlighting both its potential and limitations.

Cardiology Clinical Updates news Specialties

Acute Normovolemic Hemodilution in Cardiac Surgery: No Reduction in Allogeneic Transfusion—Insights from a Multinational Randomized Trial

By MedXY 07/31/2025

A large multinational trial found that acute normovolemic hemodilution (ANH) did not significantly reduce allogeneic red-cell transfusion in adult cardiac surgery patients, with similar safety outcomes compared to usual care.

Clinical Updates Hematology-Oncology Medical News Specialties

Mitochondrial Donation and Preimplantation Genetic Testing: Innovations in Reducing mtDNA Disease Transmission

By MedXY 07/31/2025

Mitochondrial donation by pronuclear transfer and preimplantation genetic testing effectively reduce transmission of pathogenic mtDNA variants, offering hope for families at risk of mitochondrial diseases.

Clinical Updates Hematology-Oncology Medical News Specialties

MRD-Guided Consolidation Therapy in Newly Diagnosed Multiple Myeloma: Insights from the MIDAS Phase 3 Trial

By MedXY 07/31/2025

MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.